Although Aβ deposition and tau phosphorylation are the hallmarks of AD, evidence suggests that inflammation triggered by these events and/or occurring prior to pathology contribute to onset and acceleration of functional loss and thus may be a more appropriate, broadly effective therapeutic target to prevent disease progression3. Here, MAPT is linked to Alzheimer disease.